Font Size


Menu Style



You are here: Home Department Activity

Events Calendar

Previous month Previous day Next day Next month
See by year See by month See by week See Today Search Jump to month

Association of statins, aspirin, and venous thromboembolism in women

Tuesday 25 June 2019, 15:30 - 16:30
adminHits : 3

นำเสนอโดย พญ. ลลิตา อาจารย์ที่ปรึกษา อ.สิทธิชา

Association of statins, aspirin, and venous thromboembolism in women

Gynecol Oncol. 2019 Mar;152(3):605-611. doi: 10.1016/j.ygyno.2018.12.020. Epub 2019 Jan 5.

Association of statins, aspirin, and venous thromboembolism in women with endometrial cancer.

Matsuo K, Hom MS, Yabuno A, et al.



The anti-thrombogenic effects of statins and aspirin have been reported in various malignancies but have not been well examined in endometrial cancer. This study examined the association between statin and/or aspirin use and venous thromboembolism (VTE) risk in endometrial cancer.


This is a multi-center retrospective study examining 2527 women with endometrial cancer between 2000 and 2015. Statin and aspirin use at diagnosis was correlated to VTE risk during follow-up on multivariable analysis.


There were 132 VTE events with a 5-year cumulative incidence rate of 6.1%. There were 392 (15.5%) statin users and 219 (8.7%) aspirin users, respectively. On multivariable analysis, statin use was associated with an approximately 60% decreased risk of VTE when compared to non-users (5-year cumulative rates 2.5% versus 6.7%, adjusted-hazard ratio [HR] 0.42, 95% confidence interval [CI] 0.19-0.92, P = 0.030) whereas aspirin did not demonstrate statistical significance (2.0% versus 6.5%, adjusted-HR 0.54, 95%CI 0.19-1.51, P = 0.24). There was a trend of joint effect between statin and aspirin although it did not demonstrate statistical significance: VTE risks for dual statin/aspirin user (adjusted-HR 0.27, 95%CI 0.04-2.07), statin alone (adjusted-HR 0.40, 95%CI 0.18-0.93), and aspirin alone (adjusted-HR 0.51, 95%CI 0.16-1.64) compared to non-use after adjusting for patient characteristics, tumor factors, treatment types, and survival events (P-interaction = 0.090). When stratified by statin type, simvastatin demonstrated the largest reduction of VTE risk (5-year cumulative rates 1.1% versus 6.7%, adjusted-HR 0.17, 95%CI 0.02-1.30, P = 0.088). Obesity, absence of diabetes mellitus, type II histology, and recurrent disease were the factors associated with decreased VTE risk with statin use (all, P-interaction<0.05).


Our study suggests that statin use may be associated with decreased risk of VTE in women with endometrial cancer

Location ห้องเรียน 2


JEvents v2.0.6 Stable   Copyright © 2006-2011

Login Form